(Two Studies)
Protocol Name: Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme (RTOG 0629)
Principal Investigator: Rachelle Lanciano, MD
Medical Condition: Glioblastoma (brain tumor)
Study Site Location: Delaware County Regional Cancer Center
Contact Information: Jolene Garney, RN, 610-284-8237, jolene.garney@crozer.org
Basic Eligibility: Glioblastoma that has returned following prior treatment
Summary: This study will see the effects of an experimental drug called dasatinib in the treatment of glioblastoma multiforme that has returned after previous treatment.
Protocol Name: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma (RTOG 0525)
Principal Investigator: Rachelle Lanciano, MD
Medical Condition: Glioblastoma (brain tumor)
Study Site Location: Delaware County Regional Cancer Center
Contact Information: Jolene Garney, RN, 610-284-8237, jolene.garney@crozer.org
Basic Eligibility: Within five weeks of surgery diagnosing glioblastoma
Summary: This study will compare the effect of standard doses of temozolomide with an intense dose of temozolomide in people receiving radiation therapy for newly diagnosed glioblastoma.